HC Wainwright reissued their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a report published on Friday morning, AnalystRatings.com reports. HC Wainwright currently has a $8.00 price objective on the biotechnology company’s stock.
“We reiterate our Buy rating with an $8 PT, which was derived by discounting free cash flows for each year by 25%, dividing them by our projected number of shares for each year to account for the effects of share dilution, using a 2% terminal growth rate, and a 72% probability-of-success.”,” HC Wainwright’s analyst commented.
Other research analysts have also recently issued research reports about the company. Chardan Capital restated a buy rating and issued a $15.00 price target on shares of Seres Therapeutics in a research report on Thursday, May 2nd. Cowen restated a buy rating on shares of Seres Therapeutics in a research report on Friday, February 8th. Oppenheimer restated a buy rating on shares of Seres Therapeutics in a research report on Tuesday, March 19th. Zacks Investment Research upgraded Seres Therapeutics from a hold rating to a buy rating and set a $6.25 price target for the company in a research report on Thursday, January 10th. Finally, BidaskClub upgraded Seres Therapeutics from a sell rating to a hold rating in a research report on Thursday, March 14th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $11.21.
Shares of MCRB stock opened at $5.07 on Friday. Seres Therapeutics has a fifty-two week low of $4.42 and a fifty-two week high of $9.75. The firm has a market capitalization of $207.12 million, a PE ratio of -2.09 and a beta of 1.80.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.12). Seres Therapeutics had a negative net margin of 301.60% and a negative return on equity of 1,583.95%. The firm had revenue of $7.32 million during the quarter, compared to analysts’ expectations of $8.61 million. As a group, sell-side analysts forecast that Seres Therapeutics will post -1.84 EPS for the current year.
A number of institutional investors have recently bought and sold shares of MCRB. BNP Paribas Arbitrage SA increased its position in Seres Therapeutics by 945.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,339 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 3,924 shares in the last quarter. Great West Life Assurance Co. Can purchased a new stake in Seres Therapeutics during the 4th quarter worth about $30,000. Two Sigma Investments LP purchased a new stake in Seres Therapeutics during the 4th quarter worth about $82,000. Rhumbline Advisers increased its position in Seres Therapeutics by 48.8% during the 4th quarter. Rhumbline Advisers now owns 27,136 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 8,895 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Seres Therapeutics by 7.6% during the 4th quarter. Bank of New York Mellon Corp now owns 85,364 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 6,023 shares in the last quarter. Hedge funds and other institutional investors own 79.26% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
See Also: Channel Trading
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.